We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Crossword Cybersecurity Plc | LSE:CCS | London | Ordinary Share | GB00BNG2LT65 | ORD 0.5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 4.50 | 4.00 | 5.00 | 4.50 | 4.50 | 4.50 | 35,898 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
09/11/1999 20:17 | Probably wise, I wouldn't buy in from scratch at the moment, I'm only staying because the value of my holding has become so small it's not worth selling, if the price continues to drift back I won't bother with the rights either. Maybe just maybe one day. | rd-racer | |
09/11/1999 12:07 | It is hard to get excited about this company. The name change is warranted. It has been stabilised and probably "saved" but what high value products does it have in the pipeline? Several potentials but they have all been put back into early stage clinical and pre-clinical trials. This company has a long way to go to deliver therapeutic products. It seems as those which it has, will be licenced out in early stages and hence at much lower fees and royalties than if they are developed through by the company. The SmithKline deal for otitis media and the statements by management, indicates this.
Now that it appears that most (nobby says all) of its scientific staff have gone, will it become a kind of mini BTG. Picking up the right to develop research that has been done at just a few universities and then contracting out development? However, without saying which university liaisons it has dropped and which it has kept, Cortecs/Provalis has said that it has scaled back those arrangements. Nor can I see it getting any more research grants from Australia. Better to put your money into BTG if you ask me.
So, where is its pipeline going to be fed from? What sort of smart brains does it have left. I thought that was supposed to be the main resource in a biotech.
I am selling my remaining parcel of shares. Had kept a few to see if Macrulin would generate any excitement. This is still in pre-clinical/Phase I after being put back from Phase II (conservative treatment again) and I can use my money better elsewhere. Plenty of time to come back in during Phase II/III by which time the performance of the company can be better assessed.
It seems to me that this company is going to be played conservatively and will get low returns. If I want to be invested in a healthcare/diagnosti | wojo | |
07/11/1999 22:53 | Rd-racer >>Lets just say, its hard for it to be worse... so that probably means you should feel better.... maybe. NickB >> Thanks. BTW, We had to change the name from Edge to 2C so we could TM it. :) | clem | |
07/11/1999 21:22 | Is it supposed to make me feel better or worse, worse I suspect. | rd-racer | |
07/11/1999 19:56 | This is the ultimate faller!! It tops the relative weekness charts for 12 months, 3 months and 1 month a while back. Wouldnt it be nice to buy a few, just so you can brag if it doubles! :) Heres a little model. Distance from the sun 3 month relative weekness. Anticlockwise position 1 year relative weakness, size 1 month relative weekness. (This data was taken a couple of months back). Includes all UK fallers that have experienced relative weakness over 1 year, 3 months and 1 month. Impressive huh. (By the way that is a log spiral you're looking at.) | clem | |
06/11/1999 00:56 | Apologies for the formating on the pasted bit, its gone to pot during the post. | rd-racer |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions